The study focuses on adults who have been newly diagnosed with amyloid light chain amyloidosis, a rare condition in which abnormal protein fragments build up in organs such as the heart, kidneys, or liver, leading to organ problems. The treatment being tested combines an antibody drug called belantamab mafodotin with three chemotherapy agents: cyclophosphamide, bortezomib, and dexamethasone. All four medicines are given by mouth, injection under the skin, or infusion into a vein according to a set schedule.
The purpose of the study is to see whether this combination can more effectively control the disease while remaining safe. Participants will receive the medication cycles over several months, with regular clinic visits for drug administration, blood tests, and eye examinations to watch for any side effects. The study follows each person from the start of treatment through a follow‑up period to observe how the disease responds.
Effectiveness will be judged mainly by the proportion of people who achieve a Complete Hematologic Response, meaning blood tests show no detectable disease activity. Additional assessments include improvement in the function of affected organs (heart, kidney, liver) and monitoring of eye health because the antibody can cause changes on the surface of the eye. Safety will be tracked by recording any unwanted events, changes in laboratory results, and any signs of the body forming antibodies against the new drug.
Greece 
Italy 
Spain 
